Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Bar Harbor Wealth Management

Bar Harbor Wealth Management reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 3,836 shares of the medical equipment provider’s stock after selling 330 shares during the quarter. Bar Harbor Wealth Management’s holdings in Zimmer Biomet were worth $405,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Bridge Creek Capital Management LLC boosted its position in shares of Zimmer Biomet by 1.8% during the fourth quarter. Bridge Creek Capital Management LLC now owns 26,621 shares of the medical equipment provider’s stock worth $2,812,000 after buying an additional 460 shares during the period. Reinhart Partners LLC. boosted its holdings in Zimmer Biomet by 34.4% during the 4th quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider’s stock valued at $9,164,000 after acquiring an additional 22,220 shares during the period. Thomasville National Bank grew its position in Zimmer Biomet by 1.6% in the 4th quarter. Thomasville National Bank now owns 96,969 shares of the medical equipment provider’s stock valued at $10,243,000 after acquiring an additional 1,559 shares in the last quarter. Brookstone Capital Management increased its stake in Zimmer Biomet by 34.3% during the fourth quarter. Brookstone Capital Management now owns 8,581 shares of the medical equipment provider’s stock worth $906,000 after purchasing an additional 2,193 shares during the period. Finally, Czech National Bank lifted its position in shares of Zimmer Biomet by 4.0% during the fourth quarter. Czech National Bank now owns 43,164 shares of the medical equipment provider’s stock worth $4,559,000 after purchasing an additional 1,678 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 0.8 %

Zimmer Biomet stock opened at $105.36 on Tuesday. The stock has a 50-day simple moving average of $107.97 and a 200-day simple moving average of $108.00. The company has a market capitalization of $20.97 billion, a P/E ratio of 20.03, a PEG ratio of 1.96 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $100.67 and a fifty-two week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.65 earnings per share. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be paid a $0.24 dividend. The ex-dividend date is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.91%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Wall Street Analyst Weigh In

ZBH has been the topic of several recent research reports. Oppenheimer cut their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 15th. Truist Financial upped their price objective on Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Raymond James decreased their target price on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a report on Monday, October 14th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Finally, Wells Fargo & Company lifted their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $123.33.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.